Sofia Dominguez
Payments from drug & device makers
Across 268 payments — averaging $22.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novartis$690
- Amgen$663
- UCB, Inc.$517
- GSK$451
- Radius Health, Inc.$373
- plus $2K from 18 others
What the payments were for
- Food & beverage$5,974100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 50 | $1,233 |
| Novartis | 33 | $690 |
| Amgen | 32 | $663 |
| UCB, Inc. | 23 | $517 |
| GSK | 17 | $451 |
| Radius Health, Inc. | 21 | $373 |
| Lilly USA, LLC | 20 | $365 |
| Mallinckrodt Hospital Products Inc. | 11 | $293 |
| Johnson & Johnson(2 entities) | 10 | $272 |
| Aurinia Pharma U.S., Inc. | 10 | $236 |
| Pfizer | 10 | $213 |
| E.r. Squibb & Sons, L.L.C. | 4 | $101 |
| ANI Pharmaceuticals, Inc. | 3 | $95 |
| Sanofi | 3 | $91 |
| AstraZeneca(2 entities) | 5 | $82 |
| Organon | 5 | $79 |
| Sobi, Inc | 3 | $52 |
| Bioventus LLC | 2 | $40 |
| Atricure, Inc. | 1 | $28 |
| Sandoz | 1 | $22 |
| Fresenius Kabi USA, LLC | 1 | $22 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $21 |
| Genentech USA, Inc. | 1 | $21 |
| Alvogen Inc | 1 | $17 |
How this compares
$5,975 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 20 | $133,247 |
| Humira(Cf) PenAdalimumab | 16 | $108,676 |
| Orencia ClickjectAbatacept | 20 | $41,194 |
| ProliaDenosumab | 16 | $28,048 |
| MethotrexateMethotrexate Sodium | 294 | $2,443 |
| Diclofenac Sodium | 39 | $1,344 |
| Lidocaine | 14 | $1,315 |
| Risedronate Sodium | 11 | $1,190 |
| Celecoxib | 33 | $1,116 |
| Leflunomide | 55 | $1,070 |
| Prednisone | 214 | $948 |
| Mycophenolate Mofetil | 19 | $709 |
| Gabapentin | 61 | $512 |
| Pregabalin | 23 | $437 |
| Sulfasalazine | 17 | $317 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $1,233 | $133,24720 claims |
| AmgenProlia | $663 | $28,04816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.
Other family in Miami
- Stephanie MompointMiami$4.5M
- Itsel Cardenas RamonMiami$1M
- Patrick SzarazMiami$327K
- Yamila MelendezMiami$212K
- Suzan RosenMiami$129K
- Felipe NovoaMiami$110K
- Pamela DudkiewiczMiami$89K
- Stacy FeemsterMiami$51K
- John HuffakerVenice$8M
- Miguel TrujilloMiami Gardens$4.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.